Seeking Alpha today notes an interesting development that highlights two up-and-coming Shanghai CROs. Morningside Venture, Lilly Asian Ventures and Pfizer Venture Investments have all put their money behind the Shanghai-based, bio-focused CRO HD Biosciences Inc.
HD seems to have a close relationship with Sundia, another Shanghai-based CRO that focuses on drug discovery chemistry. The two announced a service alliance with Novasecta in February, and with United PharmaTech in 2007.
No comments:
Post a Comment